Mizuho, Guggenheim, and UBS Group all lowered their price targets for GitLab (GTLB) on Wednesday. Despite the reductions, the new targets still suggest significant potential upside, with Guggenheim maintaining a "buy" rating and the most optimistic outlook. Separately, Stephens lowered its price target for Immunome (IMNM).
Comments